Reaching and Teaching Community-Based Clinicians to Improve Outcomes in CAR T-cell Therapy for DLBCL

Time Commitment:	3.5 hours over 6 weeks
Target Professions:	MD, Nurse, Nurse Practitioner, Pharmacist, DO
Target Specialties:	Family Medicine, Hematology, Internal Medicine, Oncology, Pharmacy
Credits Available:	3.5 AMA PRA Category 1 Credits™ for physicians; 3.5 ANCC Contact Hours for nurses and nurse practitioners, 3.5 ACPE Continuing Pharmacy Education Credits

• Reaching and Teaching Community-Based Clinicians to Improve Outcomes in CAR T-cell Therapy for DLBCL - Baseline Assessment

  Answer the following questions to assess your knowledge on the management of refractory/relapsed DLBCL.

• Module 1: What Does the Data Say About CAR T-cell Therapies for Patients with DLBCL?

  In self-study Module 1 you can review the effectiveness and safety data on using CAR T-cell therapies in patients with refractory and relapsed DLBCL by looking at a patient case discussion.

• Module 2: Choosing a CAR T-cell Therapy for Your Patient

  In self-study Module 2 you can review new and emerging treatment options for patients with previously treated DLBCL by looking at a patient case discussion.

• Final Assessment - Reaching and Teaching Community-Based Clinicians to Improve Outcomes in CAR T-cell Therapy for DLBCL

  Now that you have reviewed the self-study modules, answer the following questions to assess your gained knowledge on the assessment of and treatment options for refractory and relapsed DLBCL.

• Live Group Discussion #1: Gap Analysis: Review of Self-Assessment Data

  The purpose of this discussion is to review identified gaps in knowledge, competence, and confidence related to the care of patients with DLBCL, both through self-analysis and through review of the pre-assessment data.

• Live Group Discussion #2: Case Study Analyses and Action Plan Review

  The purpose of this discussion is to present the two case studies and provide an analysis of the responses. During this discussion, action plans will also be presented as we reflect on how our practice will change as a result of this CME activity.

• Case Study 1 - John Z, a 69 year old male

  Meet John Z, a 69 year old male presenting with a relapsed diffuse large B-cell lymphoma.

• Case Study 2 - AM, a 77-year-old white female

  Meet AM, a 77-year-old white female with stage 4 diffuse large B-cell lymphoma (DLBCL), concerned with treatment options and challenges to receiving treatment.

• Create an Action Plan

  In light of the information reviewed and discussed during this program, can you share an action plan that you will implement to improve the outcomes for your patients with DLBCL.

Requirements:
Group leaders should be well versed in the diagnosis, assessment, and management of patients with DLBCL and have a working knowledge of working in collaboration with other healthcare professionals. Group leaders include clinicians involved in specialized care for patients with DLBCL, clinical research studies related to choosing appropriate therapy for relapsed or refractive disease, or associated clinical teaching. Apply Now